Biotechnology News and Research

RSS

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

5 Nov 2012

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Amgen will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol, or "bad" cholesterol from the blood, at the upcoming American Heart Association Scientific Sessions 2012.

3 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

Malaysia hopes to solve nutrition transition problem

With health problems like obesity and diabetes on the rise due to changing diets in emerging economies, Malaysia is forging new linkages between domestic and international scientists and institutions in hopes of mitigating the problem.

3 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Toilet training method not related to urinary accidents in children

Parents: stop worrying about which toilet training method to use - where urinary accidents in children are concerned, it doesn't matter. This clearly-stated message, published today in Clinical Pediatrics by physician researchers from the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School and The Bristol-Myers Squibb Children's Hospital at Robert Wood Johnson University Hospital, emphasizes that the method of training chosen by parents is not the cause of urinary accidents in children.

3 Nov 2012

Physicists to bring to market new drug-discovery tool using genetic sequencing

Today physicists at Wake Forest University and NanoMedica, their biotechnology company partner, received a $700,000 grant from the National Institutes of Health to bring to market a new drug-discovery tool using next-generation genetic sequencing.

3 Nov 2012

Fluidigm unveils four innovative devices to meet challenges associated with production genomics

Fluidigm Corporation today introduced four new integrated fluidic circuits (IFCs) designed to meet the challenges associated with production genomics.

2 Nov 2012

MH6 vaccine shows promise in treating meth addiction

Scientists at The Scripps Research Institute (TSRI) have performed successful tests of an experimental methamphetamine vaccine on rats. Vaccinated animals that received the drug were largely protected from typical signs of meth intoxication.

2 Nov 2012

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2012.

1 Nov 2012

Blocking hyaluronidase activity can help repair brain damage associated with MS

Researchers at Oregon Health & Science University have discovered that blocking a certain enzyme in the brain can help repair the brain damage associated with multiple sclerosis and a range of other neurological disorders.

1 Nov 2012

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

1 Nov 2012

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

FibroGen, Inc., today announced that two abstracts relating to FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) clinical candidate for the treatment of anemia in chronic kidney disease, have been accepted for oral and poster presentations at the American Society of Nephrology (ASN) Kidney Week 2012.

1 Nov 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer's disease.

1 Nov 2012

Integra Holdings, a biopharmaceutical holding company, announced by Yissum

Yissum Research and Development Company of the Hebrew University of Jerusalem, the technology transfer company of the Hebrew University, announced today the inception of its subsidiary, Integra Holdings, a holding company focusing on biopharmaceutical companies based on inventions of researchers from the Hebrew University.

31 Oct 2012

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).

31 Oct 2012

BioXpress, AET BioTech enter agreement to co-develop Adalimumab biosimilar

AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a biosimilar version of the TNF inhibitor MAb Adalimumab.

30 Oct 2012

Biotechnology News and Research

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Malaysia hopes to solve nutrition transition problem

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Toilet training method not related to urinary accidents in children

Physicists to bring to market new drug-discovery tool using genetic sequencing

Fluidigm unveils four innovative devices to meet challenges associated with production genomics

MH6 vaccine shows promise in treating meth addiction

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Blocking hyaluronidase activity can help repair brain damage associated with MS

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

Integra Holdings, a biopharmaceutical holding company, announced by Yissum

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

BioXpress, AET BioTech enter agreement to co-develop Adalimumab biosimilar

Sprint Bioscience, TPP partner to develop small molecule inhibitors of choline kinase for cancer

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Luminex third quarter revenue increases 10% to $50.0 million

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News